ATG3 (autophagy related 3) is an E2-like enzyme essential for autophagy; however, it is unknown whether it has an autophagy-independent function. Here, we report that ATG3 is a relatively stable protein in unstressed cells, but it is degraded in response to DNA-damaging agents such as etoposide or cisplatin. With mass spectrometry and a mutagenesis assay, phosphorylation of tyrosine 203 of ATG3 was identified to be a critical modification for its degradation, which was further confirmed by manipulating ATG3 Y203E (phosphorylation mimic) or ATG3
INTRODUCTION
Macroautophagy/autophagy is a tightly regulated pathway that can be stimulated by multiple forms of cellular stress. [1] [2] [3] [4] [5] During the autophagic process, cells form double-membraned compartments, termed phagophores, which sequester damaged organelles, proteins, or portions of the cytoplasm; maturation into an autophagosome is followed by subsequent delivery of the cargo to the lysosome. 6, 7 The molecular mechanisms of autophagosome formation are evolutionarily conserved and depend upon several autophagy-related (ATG) proteins. 8 For example, BECN1
(beclin 1) can govern the autophagic process by regulating PIK3C3-dependent generation of phosphatidylinositol-3-phosphate and the subsequent recruitment of additional ATG proteins that orchestrate autophagosome formation. 9 Recently, a growing number of studies have shown that ATG proteins also play a role in autophagy-independent functions. [10] [11] [12] [13] The ATG12-ATG5-ATG16L1 protein complex, whose well-known function is participating in autophagosome formation, has an autophagy-independent role in the antiviral activity triggered by IFNG/IFN-γ. 13 Another essential protein in autophagy induction, ATG7, is also reported to induce cell cycle arrest in response to metabolic stress. 11 In addition, BECN1 participates in the association of kinetochore proteins and mitosis independent of its function in autophagy. 12 Therefore, searching for autophagy-independent functions of ATG proteins seems to be a promising field of research.
As an E2-like enzyme essential for autophagy, ATG3 can catalyze the conjugation of MAP1LC3/Atg8 and phosphatidylethanolamine (PE). 14, 15 In addition to regulating MAP1LC3-PE/MAP1LC3-II conjugation, ATG3 also forms a complex with ATG12 to regulate mitochondrial homeostasis and cell death mediated by mitochondrial pathways. [16] [17] [18] ATG3 is involved in many biological processes, mice deficient in the Atg3 gene die within the first day after birth with reduced amino acid levels. 19 However, it is unknown whether ATG3 is also involved in an autophagy-independent biological function.
PTK2/FAK (protein tyrosine kinase 2) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. 20 It can promote glucose consumption, lipogenesis, and glutamine dependency to promote cancer cell proliferation, motility, and survival. 21 Targeting PTK2 in endothelial cells is sufficient to induce tumor cell sensitization to DNA-damaging therapies by downregulating the NFKB/NF-κB pathway. 22 Small molecule PTK2 inhibitors (PTK2-Is) prevent tumor progression in mice and are being evaluated in clinical trials. [23] [24] [25] [26] [27] However, the greatest efficacy of PTK2-Is has been observed in combination with other tyrosine kinase inhibitors 28, 29 or cytotoxic drugs, 30, 31 but the real mechanism has yet to be fully revealed.
In this study, we found that in response to cancer chemotherapeutic agent treatment, PTK2
induced ATG3 phosphorylation, which led to its significant degradation but was not associated with the induction of autophagy. In addition, PTK2 inhibition caused a sustained level of ATG3, leading to a significant decrease in cell viability. These results implicate ATG3 phosphorylation in the maintenance of cell viability in response to DNA damage and also support the notion that targeting PTK2 in combination with chemotherapy is a novel cancer therapeutic strategy.
RESULTS

ATG3 is degraded during DNA damage treatment
ATG proteins have been reported to exert autophagy-independent functions. For example, ATG5 expression is induced by DNA-damaging agents and promotes mitotic catastrophe 5 independent of autophagy. 32 Therefore, we examined several ATG protein levels in response to treatment with DNA-damaging drugs. Human colon cancer cell lines HCT116 and LoVo were treated with etoposide for 3 h or cisplatin for 6 h, washed, and incubated with fresh medium. As shown in Figure 1A -D, among the ATG proteins tested, only ATG3 protein levels were gradually decreased after etoposide or cisplatin treatment. To verify whether this phenomenon was cell type-dependent, the levels of ATG proteins were also measured in the cervical cancer cell line HeLa and osteosarcoma cell line U2OS after etoposide treatment. Consistent with the previous results, ATG3 was decreased at the protein level ( Figure S1A -B). Furthermore, we used irradiation (IR) or camptothecin to treat HCT116 cells and found that this is a general phenomenon that occurs in response to DNA damage inducers ( Figure S1C-D) .
Because etoposide or cisplatin treatment had no effect on ATG3 mRNA levels ( Figure 1E -F), protein degradation might be responsible for the decrease in ATG3 protein levels in response to DNA-damaging drug treatment. To determine the pathways involved in the ATG3 degradation, we pretreated HCT116 cells with a panel of inhibitors that included the proteasome inhibitor MG132 and the lysosome inhibitor chloroquine (CHQ). Treatment with MG132 significantly blocked the etoposide-induced reduction of ATG3 levels, but CHQ had no such effect on ATG3 degradation ( Figure 1G ), suggesting that ATG3 is degraded by the proteasomal pathway in response to etoposide treatment.
Next, to determine whether ubiquitination is required for ATG3 degradation, an HA-ubiquitin plasmid was transfected into HCT116 cells; ATG3 ubiquitination was detected by co-IP with an anti-ATG3 antibody followed by immunoblotting with an anti-HA antibody. As shown in Figure   1H , ATG3-conjugated ubiquitin after etoposide treatment was increased in comparison with that in 6 untreated cells. These results demonstrate that the degradation of ATG3 occurs mainly through a ubiquitin-proteasome-dependent pathway.
PTK2 regulates ATG3 degradation
To test whether the post-translational modifications of ATG3 play a role in its degradation, a protein extract of HCT116 cells was immunoprecipitated with an anti-ATG3 antibody and probed with an anti-phosphorylated serine, an anti-phosphorylated threonine, an anti-phosphorylated tyrosine or an anti-acetylated lysine antibody. Acetylation of ATG3 at lysine and phosphorylation of ATG3 at serine or threonine did not show a significant change in HCT116 cells in response to etoposide treatment ( Figure S2A -B). By contrast, a significant increase in phosphorylated ATG3 at a tyrosine was detected in etoposide-treated HCT116 cells (Figure 2A ), suggesting that ATG3 tyrosine phosphorylation may be involved in regulating its stability.
Next, we used several well-characterized tyrosine kinase inhibitors, SRC Inhibitor-1, an inhibitor of SRC; Erlotinib, an inhibitor of EGFR; and PF-573228, an inhibitor of PTK2, to investigate which cellular signaling pathway is involved in ATG3 degradation. HCT116 cells were pre-incubated with SRC Inhibitor-1, erlotinib or PF-573228 for 1 h followed by treatment with etoposide for another 3 h. Forty-eight h after etoposide treatment, blockage of PTK2 by PF-573228 completely inhibited etoposide-induced ATG3 degradation, whereas the others did not ( Figure 2B ). To further confirm the role of PTK2 in ATG3 degradation, HCT116 cells were transfected with either nonspecific or PTK2-specific siRNA, and ATG3 degradation was then detected. The efficiency of the RNAi against PTK2 was significant, and, as expected, upon etoposide treatment ATG3 was degraded in the cells transfected with the negative control siRNA.
In contrast, ATG3 remained at higher levels in the cells transfected with the PTK2 siRNA ( Figure   7 2C), suggesting that PTK2 plays a critical role in ATG3 degradation in response to DNA damage.
Y203 phosphorylation of ATG3 is required for its degradation
To test which phosphorylation site is critical for ATG3 degradation, we purified the ATG3
protein and performed an analysis with mass spectrometry (MS). As shown in Figure S3 , a mass spectrometry analysis indicated that a highly conserved site, Y203, of ATG3 was phosphorylated after etoposide treatment. To further confirm this site, we generated an antibody for the Y203-phosphorylated peptide of ATG3 ( Figure 3A) . Using this antibody, we found that Y203-phosphorylated ATG3 was increased after etoposide treatment ( Figure 3B ). Moreover, etoposide-induced ATG3 phosphorylation at Y203 was downregulated by the PTK2 inhibitor PF-573228 ( Figure 3C ).
To further confirm the role of ATG3 phosphorylation at Y203 in its degradation, we generated ATG3 wild-type (ATG3-WT), ATG3
Y203E
(phosphorylation-mimic) and ATG3
Y203F
(phosphorylation-incompetent) inducible cell lines in Atg3 KO MEFs. As shown in Figure 3D and E, ATG3 was a relatively stable protein, with a half-life in excess of 12 h. In contrast, the half-life of the phosphorylation-mimic protein ATG3 Y203E was significantly shortened to 3 h. This reduction in the half-life of ATG3 Y203E resulted from an increasing ubiquitination of ATG3. As shown in Figure 3F , ATG3 Y203E -conjugated to ubiquitin was greatly increased compared to wild-type ATG3.
The above results demonstrate that phosphorylation of ATG3 at Y203 is associated with its ubiquitination, which destabilizes the ATG3 protein under DNA damage conditions.
Y203 phosphorylation of ATG3 is dispensable for autophagy induction.
Because ATG3 is an autophagy essential gene, we next investigated the role of 
ATG3 Y203F promotes DNA damage-induced mitotic catastrophe by inhibiting BAG3
Previous studies have shown that some autophagy-related proteins can affect the DNA repair process. [32] [33] [34] [35] [36] Next, we tested whether sustained levels of ATG3 could regulate this process.
Homologous recombination (HR) and nonhomologous end-joining (NHEJ) are 2 major pathways for the repair of DNA double-strand breaks. 37 Therefore, we used the direct-repeat (DR)-GFP reporter and the pEJ5-GFP reporter to monitor the HR and NHEJ pathways, respectively. As shown in Figure S4A -B, the efficiency of HR or NHEJ did not substantially change between the ATG3-WT cell line and ATG3 Y203F cell line, suggesting that Y203 phosphorylation is not involved 9 in the DNA repair process.
In addition to the involvement of ATG3 in autophagy, overexpressed ATG3 induces apoptosis in extracellular matrix (ECM)-attached colorectal cancer cells. 38 To investigate whether ATG3 degradation affects apoptosis, we used the ATG3-WT or ATG3
Y203F
-inducible cell lines for flow cytometry analysis. As shown in Figure S5 , in response to etoposide treatment, there was no obvious difference in the apoptosis process between the ATG3-WT cell line and ATG3 Y203F cell line.
As several reports have demonstrated that DNA-damaging agents are able to induce mitotic catastrophe, 32, 39, 40 we investigated the changes in nuclear morphology between ATG3-WT and These results suggest that sustained ATG3 may be able to promote DNA damage-induced mitotic catastrophe.
We next focused on the potential mechanisms of action for ATG3. It has been reported that ATG3 is able to interact with BAG3 (BCL2 associated athanogene 3), 41 which plays an important role in mitotic catastrophe. 42 As shown in Figure 5F , we found that the interaction between ATG3
and BAG3 was enhanced in response to etoposide treatment. These results suggest that ATG3 may promote DNA damage-induced mitotic catastrophe through its interaction with BAG3.
Sustained ATG3 is related to the inhibition of cell growth in response to DNA-damaging agents
Next, we generated an ATG3 knockout HCT116 cell line using the CRISPR/Cas9 system.
Plasmids encoding ATG3-WT and ATG3 Y203F were separately transfected into the ATG3 knockout HCT116 cell line ( Figure 6A ). Subsequently, we tested the colony formation of the ATG3-WT and 
DISCUSSION
In this study, we identified an autophagy-independent function of ATG3 during the DNA damage process. After treatment with DNA-damaging agents, PTK2 phosphorylates ATG3 at Y203, through which the degradation of ATG3 is promoted via the ubiquitin-proteasome-dependent pathway. Inhibition of PTK2 combined with DNA-damaging drug treatment causes sustained levels of ATG3, leading to a significant decrease in cell proliferation in a mitotic catastrophe-dependent manner.
Previous studies have shown that several autophagy-related proteins can be degraded through the proteasomal pathway. [43] [44] [45] [46] [47] [48] For example, ubiquitin E3 ligase RNF5 interacts with ATG4B and controls ATG4B stability through proteasome-dependent degradation. 44 In addition, free ATG12 is highly unstable and rapidly degraded by the proteasomal pathway. 45 These results suggest that autophagy-related regulators may be regulated by the ubiquitin-proteasome system. Although ATG3 is very stable in normal conditions ( Figure 3D ) 49 , our data showed that ATG3 can also be ubiquitinated and degraded under the conditions of DNA damage (Figure 1) . Consistently, it has already been reported that there are several potential ubiquitination sites on ATG3. 50, 51 Therefore, further studies need to be performed to determine whether these ubiquitination sites are also responsible for ATG3 degradation in response to DNA-damaging agents.
As a protein-conjugating enzyme for MAP1LC3 lipidation, the biological function of ATG3 is mainly focused on autophagy. 14, 15 The fact that autophagy protects cells from genotoxic stress and maintains genome integrity has already been established. 33, [52] [53] [54] [55] [56] Autophagy, however, is unlikely itself to be responsible for the DNA damage-induced tumor cell growth inhibition. It has been reported that very low levels of ATG5 expression are sufficient for autophagy induction.
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Similar to ATG5, we also found that although a majority of ATG3 was degraded after etoposide treatment, autophagy could still be induced by the small amount of non-degraded ATG3 ( Figure   4D ). These results are consistent with previous reports that show incomplete deletion of Atg3 in macrophages can still allow MAP1LC3 lipidation. 58 In addition, we found that sustained levels of ATG3 induced by PTK2 inhibition can still sensitize cancer cells to DNA-damaging reagents in autophagy-deficient cells ( Figure S7A-B) , suggesting that autophagy is not crucial for ATG3 mediated inhibition of cell growth in response to DNA damage. Thus, we speculate that activity of ATG3 other than autophagy induction, leads to its crosstalk with the DNA damage response pathway. Recent evidence has shown that overexpressed ATG3 triggers apoptosis in the ECM-attached colorectal cancer cells. 38 However, in our system, we found that there was no difference between ATG3-WT and ATG3 Y203F in the apoptosis process after DNA-damaging drug 13 treatment ( Figure S5 ). Instead, we found sustained levels of ATG3 were able to enhance DNA damage-induced mitotic catastrophe ( Figure 5 ), and this might be a new function of ATG3 independent of autophagy and apoptosis.
Furthermore, we also revealed that ATG3 may take part in the mitotic process by binding BAG3. As a member of the BAG family of co-chaperones that interacts with HSPA (heat shock protein family A [Hsp70] member), BAG3 can regulate many important biological processes such as development, apoptosis and autophagy. 59 Recently, a novel HSPB8-dependent mitotic function of BAG3, which can guide spindle orientation and proper chromosome segregation, has been uncovered. 42 In addition, a proteomic study of BAG3 showed that ATG3 is a newly identified binding partner. 41 In this study, we observed an increase in levels of interaction between BAG3
and ATG3 in response to DNA-damaging drug treatment ( Figure 5F ). Accordingly, we postulate that ATG3 can inhibit the mitotic function of BAG3 after DNA-damaging drug treatment, which may be mediated by interfering with the formation of the BAG3 protein complex. When degradation of ATG3 was blocked after DNA-damaging drug treatment, the increased levels of ATG3 could sequester more BAG3, which may improve the suppression of BAG3 activity, leading to enhanced DNA damage-induced mitotic catastrophe.
Accumulating evidence suggests that PTK2 can promote cancer cell proliferation, motility, and survival. 21 These multiple functions of PTK2 work through kinase-dependent or kinase-independent mechanisms. As a protein tyrosine kinase, PTK2 can activate the phosphoinositide 3-kinase-AKT1 pathway by binding with the PIK3R/p85 subunit of phosphoinositide 3-kinase 60 to induce survival signals and prevent cancer cell death. 31, 61, 62 Targeting of PTK2 in endothelial cells is sufficient to induce tumor cell sensitization to 14 DNA-damaging therapies by downregulating the NFKB pathway. 22 Additionally, a recent study showed that some ATG proteins can colocalize with PTK2 and PXN. 63 Consistently, our data showed that in response to treatment with DNA-damaging agents, PTK2-induced ATG3 phosphorylation led to its degradation. Furthermore, PTK2 inhibition combined with DNA-damaging drugs induced sustained levels of ATG3, leading to a significant decrease in cell viability.
Previous studies have shown that PTK2 is overexpressed and activated in several inhibitor, can inhibit cell growth in vitro and in vivo and enhance the efficacy of chemotherapy. 27 Consistent with previous reports, we demonstrated that sustained levels of ATG3 induced by PTK2 inhibition can sensitize cancer cells to DNA-damaging reagents both in vitro and in vivo.
We also found that among several tyrosine kinase inhibitors, the PTK2 inhibitor had a much stronger effect on cancer cell colony formation when combined with DNA-damaging agents in this study. Although the specific mechanism of the tumor suppression function of ATG3 is not clear, targeting PTK2 combined with chemotherapeutic agents may be a useful strategy for the development of novel cancer therapies in the future.
In conclusion, our results showed that ATG3 is phosphorylated and degraded in response to 15 cancer chemotherapeutic agents in a PTK2-dependent manner. Sustained levels of ATG3 after a combination regimen result in a significant decrease in cell viability in cancer cells through a mitotic catastrophe-dependent manner. Further studies exploring the mechanism of PTK2 inhibitors in combinatorial therapies will help us promote the rational use of chemotherapy drugs.
METHODS
Reagents
Etoposide (E1383), cisplatin (P4394), chloroquine (C6628), PF-573228 (PZ0117), SRC Inhibitor-1 (S2075), doxycycline (D9891) and Anti-Flag M2 beads (A2220) were purchased from Sigma-Aldrich; erlotinib (S1023) was purchased from Selleck Chemicals; MG132 (474790) was purchased from Merck; and Tet System Approved fetal bovine serum (631106) was purchased from Clontech. (Invitrogen, 11668-027) was used following the manufacturer's instructions, while the Neon transfection system (Invitrogen, MPK5000) was used for transfection of MEF cells.
Establishment of ATG3-inducible MEF cell lines
The ATG3-inducible cell line was generated using the pTRIPZ-ATG3 WT, Y203E and Y203F
plasmids. Plasmids were transfected into Atg3 knockout MEF cells, and the stable cell line was established by selection with 4 μg/ml puromycin (Sigma-Aldrich, P8833).
Generation of Cas9 ATG3 knockout and PTK2 knockdown cell lines
The Cas9 ATG3 knockout cell lines were generated using CRISPR-Cas9 methods in HCT116 17 cells. We used the SpCas9-2A-Puro vector purchased from Addgene (#48139; deposited by Feng Zhang). 69 The ATG3 gRNA was designed by online software (http://crispr.mit.edu), and the gRNA sequence of ATG3 was 5'-GTGAAGGCATACCTACCAAC-3'. The plasmids were transfected into HCT116 cells and selected with 2.5 μg/ml puromycin. The stable PTK2 knockdown cell lines were established by a PTK2-specific RNAi plasmid. The nonspecific or shPTK2 plasmids were transfected into HCT116 cells and selected using 500 μg/ml hygromycin B (Roche, 10843555001).
Immunoblot analysis
Equal amounts of proteins were size-fractionated by 7.5-15% SDS-PAGE. For immunoprecipitation, cells were harvested and then lysed in a Nonidet P40 buffer (1% Nonidet P40 [Amersco, E109], 150 mM NaCl, 50 mM Tris at pH 7.5, and 5 mM EDTA) supplemented with complete protease inhibitor cocktail (Roche, 5892791001) and phosphatase inhibitor cocktail (Applygen, P1260). Whole-cell lysate proteins were used for immunoprecipitation with the indicated antibodies. Generally, 2 µg of antibody was added to 1 ml of cell lysate, which was incubated at 4°C for 8 to 12 h. After the addition of protein G-agarose beads (GE Healthcare, 17-0618-01), the incubation was continued for 2 h. Immunoprecipitates were extensively washed with lysis buffer and eluted with SDS loading buffer by boiling for 5 min. All bands of blots were scanned with a phosphorimager, and the relative intensity of each band was normalized to each band of ACTB. The data collected came from at least 3 independent experiments.
Real-time PCR analysis of mRNA
Total RNA was isolated with TRIzol reagent (Invitrogen, 15596026). The cDNA was synthesized 
Colony formation assay
Cells were plated and exposed to 40 μM etoposide for 3 h. Then, etoposide was removed by washing 3 times. Cells were trypsinized and plated into 60-mm plates. After 2 weeks, methanol fixation and staining with methylene blue was undertaken to identify visible colonies. Plating efficiencies were calculated as follows: number of colonies formed/number of cells plated.
Surviving fractions were calculated as follows: number of colonies formed/number of cells plated (treated) x plating efficiency (untreated).
WST-1 assay
Equal 
